Effects of nVNS on Stress Reactivity in IBS
A legfontosabb adatok
- Ki végzi
- University of California, Los Angeles
- Hol
- Los Angeles (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 200 fő, tervezett
- Kezdés
- 2026. dec. 1.
- Várható befejezés
- 2031. dec. 1.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Truvaga Plus
- A regiszteradat frissítve
- 2026. november 9.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with at least moderate irritable bowel syndrome (IBS) with diarrhea or mixed bowel habits. People are randomly put into a group that uses a handheld neck nerve-stimulation device at home for 8 weeks, or a usual care group.
- Életkor
- 18 to 50 years
- Nem
- All sexes can join. Women must not have reached menopause and must have generally regular periods.
- A betegség stádiuma
- IBS-D or IBS-M by Rome V criteria, at least moderate severity (IBS-SSS ≥175).
- Korábbi kezelés
- No hormonal medicines, including birth control or hormone replacement therapy, now or in the last 3 months. No plan to start a new IBS treatment during the 8-week study period.
A részvétel fő kizáró okai
- Obesity (BMI > 30), pregnancy, or being in or past menopause.
- Another bowel disease that could explain the symptoms, such as inflammatory bowel disease or celiac disease.
- Any implanted electrical device, metal near the neck, or anything that makes MRI unsafe.
- Heart disease, heart attack within 5 years, or significant blood pressure or heart rate problems.
- Past abdominal surgery other than appendix, gallbladder, benign polyp removal, or hiatus hernia.
A regiszter feltételei, szó szerint
Mind a 25 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18-50 years
- Meets Rome V diagnostic criteria for IBS-D or IBS-M
- At least moderate IBS symptom severity, defined as IBS-SSS ≥175
- For females: premenopausal with generally regular menstrual cycles and willing to complete study visits within the study-specified menstrual-cycle window when feasible
- Able to understand and provide informed consent in English
- Willing and able to complete questionnaires, biospecimen collection, wearable monitoring, MRI procedures, and randomized study requirements
Ki nem vehet részt
- Evidence or history of another gastrointestinal disease that could explain symptoms, including inflammatory bowel disease or celiac disease, unless adequately excluded by clinical evaluation or prior testing
- Previous use in the last 3 months OR current use of hormonal medications, including hormonal contraceptives (i.e. birth control pills, patches, implants, or intrauterine devices (IUDs)) or hormone replacement therapy
- MRI contraindication, including a non-removable ferromagnetic implant or device, prior significant tattoo-related heating or burns, severe claustrophobia that cannot be managed, or another condition judged unsafe for MRI
- Past abdominal surgery (except for appendectomy, cholecystectomy, benign polypectomy, hiatus hernia)
- Major active psychiatric illness (e.g., schizophrenia, bipolar disorder), significant neurologic or central nervous system disease, or another medical condition that could affect safety, adherence, or interpretation of study outcomes
- Dermatologic conditions affecting the neck region that would interfere with nVNS placement
- History of cervical vagotomy
- Movement disorder
- Clinically significant hypertension, hypotension, bradycardia, or tachycardia
- Cardiac disease or atherosclerotic cardiac disease, including congestive heart failure, known severe coronary artery disease, or recent myocardial infarction within 5 years
- Individuals with obesity (BMI > 30)
- Pregnancy or a positive pregnancy test
- Perimenopausal or postmenopausal status
- Current participation in another IBS-specific intervention study or planned initiation of a new IBS-directed treatment during the 8-week randomized period
- Contraindication to cervical nVNS or inability to use the device safely
- Any implanted electrical device
- Any metallic device implanted at or near the neck
- Use of another electrical device at the same time (e.g., TENS unit, muscle stimulator) or any portable electronic device
- Inability or unwillingness to provide informed consent or complete study procedures in English
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 50 év között vagy?
Helyszínek itt: Egyesült Államok
- University of California, Los AngelesLos Angeles, Egyesült ÁllamokContact: Michelle ChoyToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
Irritable bowel syndrome (IBS) is a chronic disorder of gut-brain interaction that causes abdominal pain and altered bowel habits. Many people with IBS also experience symptoms outside the bowel, such as headaches, widespread pain, poor sleep, anxiety, and depression; these symptoms are especially common in females. This study focuses on stress reactivity (SR), a persistent pattern of stress-system activity that may be linked to autonomic nervous system function, immune activity, the gut microbiome, and brain processing. The investigators will enroll adults with at least moderate IBS symptoms and randomly assign them to 8 weeks of non-invasive vagal nerve stimulation (nVNS) or Usual Care. Participants assigned to nVNS will use a handheld device on the left side of the neck at home twice daily. The investigators will compare changes in IBS severity and other physical symptoms and examine whether baseline or treatment-related changes in blood, stool, heart-rate variability, sex hormones, and brain imaging measures are associated with response. The study will also explore whether treatment effects and predictors differ by sex.
A vizsgálat 2 csoportja
- nVNSMár használt kezelés, összehasonlításként
Device: Participants will self-administer a transcutaneous cervical nVNS device, Truvaga Plus, which is identical to GammaCore but is rechargeable. Truvaga Plus is classified as a general wellness product that does not require FDA clearance and can be purchased without a prescription (electroCore LLC, Basking Ridge, NJ, USA, letter of support). Usage: The nVNS will be delivered via two stainless steel contact surfaces that are coated with conductive gel before each treatment. The device will be positioned in parallel with the carotid pulse on the left side of the neck. Two back-to-back 2-minute nVNS stimulations (4 minutes total) will be administered twice daily at home for 8 weeks. Intensity: Level is dependent on the patient. They will be instructed to increase the intensity until they feel a strong but comfortable sensation-tingling or a slight lip pull is common. Most users find the ideal intensity between levels 4 and Frequency: 2 sessions, 2x daily; 224 sessions total
Kezelés: Truvaga Plus
- Usual careNincs vizsgálati kezelés, összehasonlításként
Participants assigned to the Usual Care arm will undergo the same assessments as those in the nVNS arm but will not receive any specific intervention from the project. No restrictions will be placed on participants, except that they will be asked not to start any new therapies for IBS or any new medicines unless deemed necessary by their healthcare provider.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Effects of Non-invasive Vagal Nerve Stimulation on Clinical, Peripheral Biologic, and Brain Measures of Stress Reactivity in Irritable Bowel Syndrome: a Randomized Controlled Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07926945: ki vehet részt
- A regiszteradat frissítve
- 2026. november 9.